Accendra Health, Inc. (ACH) is a Glen Allen, Virginia-based provider of home-based care products and services through the Apria and Byram Healthcare brands; it was formerly known as Owens & Minor and began trading under its new name and symbol in January 2026. The stock closed Monday at $0.0857, down $0.0463, or 35.08%, from Friday's close of $0.1320 — a decisive move downward to an all-time low. The immediate reason cited by the market was the exchange's move to begin delisting the shares, a step the company had been fighting since early October.
NYSE Regulation determined that the common stock is no longer suitable for listing because of "abnormally low selling price" levels under Section 802.01D of the Listed Company Manual and said trading would be suspended immediately. The exchange will apply to the Securities and Exchange Commission to delist the stock once all procedures, including any company appeal to a committee of the NYSE board, are complete. The action supersedes earlier cures: the company received a notice on Oct. 6 for trading below $1.00 over 30 sessions and a second notice in late October for failing minimum market capitalization and equity thresholds, then submitted a compliance plan built largely around a reverse stock split slated for a December shareholder vote. That remedy is now overtaken by the delisting decision.
The listing failure is a symptom, not the disease. Third-quarter results published Nov. 5 showed an adjusted loss of $0.23 per share against expectations near break-even and revenue of $601.8 million, down 14% year over year and below consensus. Adjusted EBITDA roughly halved to $47.8 million as payer audits delayed collections and squeezed roughly $10 million of revenue and profit out of the quarter. Management cut full-year 2026 revenue guidance to $2.45 billion–$2.55 billion and adjusted EBITDA to $300 million–$320 million, while cash fell to $26.6 million from $282.0 million at the start of the year. Against roughly $1.8 billion of debt and negative shareholders' equity, the equity's residual value is what the price now debates.
Options markets added to the pressure: exchange notices confirmed ACH options will be delisted from several options exchanges effective Nov. 17, removing a hedging and speculation outlet precisely when holders wanted one.
Volume of about 3.2 million shares was roughly 1.2 times the 50-day average near 2.6 million — elevated, but restrained for a listing event, consistent with a thin order book in a sub-$0.10 name. The stock set an intraday low of $0.0817, broke decisively below every recent support level, and now trades about 98% below its 52-week high of $4.69. The move was idiosyncratic rather than sector-driven; home-care and medical-distribution peers did not mirror a decline of this scale, and the selloff reflects the specific loss of exchange listing and access to public capital. A post-close announcement that Blue Shield of California expanded its collaboration with Apria and Byram was far too small to offset the listing news.
The score runs from 0 — no meaningful news and a move that is normal for the stock — to 100, meaning transformative news and an extreme, rare price move. Here the score is 75 out of 100. The verified news is materially significant: an exchange commencing delisting proceedings is close to a terminal event for a micro-cap equity and directly threatens liquidity and index eligibility. The price move was also far outside normal: the 35.08% decline was roughly five times the stock's average absolute daily move of about 6.9% over the last 60 sessions, and no session in that window produced a larger one-day drop, though a 31.87% slide on Nov. 6 came close. Strong news plus an unusually large move combine into the score.
The company can request a review by a committee of the NYSE board, and the timing and outcome of that process are the nearest swing factors; absent a successful appeal, trading would migrate to the over-the-counter market, where spreads widen and institutional participation typically disappears. The planned reverse split still faces a December shareholder vote, but even approval would not automatically restore the listing. Operationally, investors will focus on fourth-quarter results expected Feb. 24, 2027, cash burn and liquidity, the pace of payer-audit collection delays, and whether asset sales or further liability management can stabilize a leveraged balance sheet. A leadership transition — with a new chief executive installed and the chief operating officer stepping into an advisory role — adds execution risk to an already narrow path.
Tickeron's Trending AI Robots page curates the bots that are performing best in current market conditions from a library of hundreds of AI trading bots covering thousands of tickers. Because bots differ widely by strategy, timeframe, performance metrics and traded symbols, the trending list offers a practical starting point for comparing approaches side by side. Readers looking for ideas beyond a single distressed name may find it a useful next stop.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
Moving higher for three straight days is viewed as a bullish sign. Keep an eye on this stock for future growth. Considering data from situations where ACH advanced for three days, in 220 of 288 cases, the price rose further within the following month. The odds of a continued upward trend are 76%.
The RSI Indicator shows that the ticker has stayed in the oversold zone for 7 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an Uptrend is expected.
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 6 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
The Momentum Indicator moved below the 0 level on November 06, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on ACH as a result. In 78 of 85 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 90%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where ACH declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 88%.
The Aroon Indicator for ACH entered a downward trend on November 17, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
The Tickeron PE Growth Rating for this company is 6 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 21 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (-0.028) is normal, around the industry mean (14.423). P/E Ratio (-0.051) is within average values for comparable stocks, (11.188). Projected Growth (PEG Ratio) (0.090) is also within normal values, averaging (2.016). Dividend Yield (0.013) settles around the average of (0.134) among similar stocks. P/S Ratio (0.031) is also within normal values, averaging (4.260).
The Tickeron Seasonality Score of 85 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Price Growth Rating for this company is 98 (best 1 - 100 worst), indicating slightly worse than average price growth. ACH’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ACH’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 74, placing this stock worse than average.
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
a manufacturer of alumina, primary aluminum and aluminum fabricated products
Industry MedicalDistributors